Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. September 2025 10:00 ET | Quelle: NanoNewron

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program

NanoNewron awarded a $2.5 million NIH grant to develop TNF-α inhibitors engineered to cross the Blood-Brain Barrier to treat Alzheimer’s disease
04. März 2025 15:13 ET | Quelle: NanoNewron

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound

Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier
20. Februar 2025 12:30 ET | Quelle: NanoNewron

NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today

NanoNewron, a biotech company developing biologics crossing the blood-brain barrier to treat Alzheimer’s, was featured by Rutgers University Newsletters